Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?
Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey.
M A
MA
Sendur
S
S
Aksoy
Y
Y
Ozdemir
N
N
Zengin
K
K
Altundag
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab